Accretion Pharmaceutical’s IPO was subscribed 7.67 times on the last day, a retail quota was subscribed over 10.54 times, NII was subscribed over 4.28 times, and QIB was subscribed 12.14 times, respectively.
Details About Accretion Pharmaceuticals IPO
Accretion Pharmaceuticals got approval from SEBI for an IPO of around ₹29.75 crores. Accretion Pharmaceuticals IPO consists of fresh issues of ₹29.75 crores with a face value of ₹10 each. Further, Accretion Pharmaceuticals had a set price band of ₹96 to ₹101 Per Share.
In the Accretion Pharmaceuticals IPO, 1,200 shares were in 1 lot size for the retail minimum and maximum categories as well. Moreover, 2,400 shares were in 2 lot sizes for the S-HNI category.
To invest in the Accretion Pharmaceuticals IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum and maximum investment of 1,21,200.
- SHNI (S-HNI): Minimum investment of ₹2,42,400.
Accretion Pharmaceuticals IPO’s Subscription Duration
The opening date of Accretion Pharmaceuticals’ IPO was on May 14, 2025, and the closing date was on May 16, 2025. The allotment date of the Accretion Pharmaceuticals IPO was on May 19, 2025, and the investors will receive a refund on May 20, 2025. Accretion Pharmaceuticals is set to be listed on May 21, 2025.
Accretion Pharmaceuticals’ IPO funds deployment
- The proceeds raised from the funds will be used to handle the purchase of new equipment/machinery, etc.
- The funds raised will be used towards the upgradation of the existing manufacturing facility
- Some funds will be used for the Repayment/prepayment of certain borrowings availed by the Company.
- Lastly, the remaining funds will be utilized for the company’s General Corporate Purpose
About Accretion Pharmaceuticals Company
Incorporated in 2012, Accretion Pharmaceuticals Limited is one of the growing pharmaceutical companies engaged in the manufacturing and marketing of Tablets, Capsules, and other healthcare products. Accretion Pharmaceutical Company is known to manufacture various types of pharmaceutical products for other brands as well via license agreements or contract manufacturing. The manufacturing facility is situated in Ahemdabad, Sanand, Gujarat. Accretion Pharmaceutical has established its presence in more than 20 countries by expanding its business in various regions such as Africa, Southeast Asia, and the Middle East. The company comprises a total of 83 employees, including 4 Executive Directors, as of January 2025. The company has achieved various certifications, showcasing its commitment to the quality and environmental standards.
Financial Report of the Accretion Pharmaceuticals Company
The company reported revenue of ₹33.94 crores in 2024 against ₹29.53 crores in 2023. The company reported a profit of ₹3.88 crores in 2024 against a profit of ₹0.10 crores in 2023.
